COPENHAGEN and SAN FRANCISCO, March 17 /PRNewswire/ -- CCBR – SYNARC, the world's leading provider of centralized imaging, molecular marker analyses and multinational clinical research facilities to the pharmaceutical and biotechnology industry, announced today that Claus Christiansen, M.D., has been appointed Chief Executive Officer of the company.
Dr. Christiansen is returning to an executive management role with the company, having founded CCBR in 1992 and, along with Harry K. Genant, M.D. and others, SYNARC in 1998. "Advancing clinical research through scientific excellence is at the core of our company. I look forward to continuing to work with our talented team of dedicated employees to deliver outstanding service to sponsors," stated Dr. Christiansen.
Herve Girsault, the outgoing CEO, will continue to advise CCBR- SYNARC's Board of Directors and management on strategic and corporate development matters. "On behalf of the Board of Directors, I thank Herve for his many significant accomplishments during his tenure as CEO. Under Herve's leadership, the company successfully commenced the largest clinical trial in history and achieved financial stability," stated Dr. Christiansen.
Dr. Christiansen, Dr. Genant, and Henrik Sanders continue to comprise the Board of Directors of the company.
Ralph Reyes has been appointed Head of the CCBR Division. Aaron Timm has been appointed Head of the Imaging Division. Scott Woodward will continue in his role as Head of the Biochemical Markers Division.
CCBR - SYNARC is a leader in providing advanced central imaging analysis, molecular markers and clinical research facilities enabling pharmaceutical, biotechnology and medical device industry clients to accelerate clinical trials, enhance the likelihood of success and reduce the cost of developing novel therapies. CCBR - SYNARC currently supports more than 150 clinical trials, involving more than 100,000 patients at 2,500 sites worldwide. CCBR - SYNARC operates out of offices in eleven countries.